TABLE 2

Primary and Secondary Outcomes

OutcomeControl Group (n = 143)SLI Group (n = 148)Unadjusted Odds Ratio (95% CI)PAdjusted Odds Ratio (95% CI)a
Primary outcome, n (%)
 MV within the first 72 h of life 93 (65)79 (53)0.62 (0.38–0.99).040.57 (0.33–0.96)
Secondary outcomes, n (%)
 MV within the first 3 h of life 73 (51)66 (45)0.77 (0.49–1.22).270.72 (0.43–1.22)
 BiPAP47 (33)63 (43)1.51 (0.94–2.44).091.51 (0.93–2.43)
 Nasal IMV 36 (25)39 (26)1.06 (0.63–1.80).851.07 (0.63–1.81)
 Surfactant 110 (77)109 (74)0.84 (0.49–1.43).520.88 (0.50–1.56)
 SIMV/SIPPV/PSV90 (63)86 (58)0.82 (0.51–1.31).430.84 (0.51–1.39)
 HFV 31 (22)32 (22)1.00 (0.57–1.74).991.03 (0.58–1.83)
 Any mechanical ventilation 98 (69)88 (59)0.67 (0.42–1.10).110.68 (0.41–1.13)
 BPDb,c50 (35)57 (39)1.17 (0.80–1.71)d.421.14 (0.78–1.69)d
 Deathc12 (8)17 (11)1.37 (0.66–2.88)d.401.39 (0.66–2.93)d
  • BiPAP, bilevel positive airway pressure; HFV, high-frequency ventilation; PSV, pressure support ventilation; SIMV, synchronized intermittent MV; SIPPV, synchronized intermittent positive pressure ventilation.

  • a Adjusted for center and gestational age.

  • b Defined by the use of supplemental oxygen at a postmenstrual age of 36 weeks.

  • c Proportions are estimates of cumulative incidence of events in the presence of competing risks.

  • d Unadjusted hazard ratio (95% confidence interval).